<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421495</url>
  </required_header>
  <id_info>
    <org_study_id>LCSY-TB-2020-002</org_study_id>
    <nct_id>NCT04421495</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China</brief_title>
  <official_title>Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chest Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor and evaluate the safety and effectiveness of&#xD;
      Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for&#xD;
      treatment of MDR-TB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, multicenter, phase Ⅳ, open-label trial to evaluate the safety and&#xD;
      effectiveness of delamanid-containing regimen in men and women aged 18 to 65 years with&#xD;
      microbiologically confirmed pulmonary MDR-TB in China. A target of 600 participants will be&#xD;
      enrolled. The study will consist of a screening phase of up to 8 weeks, an open-label study&#xD;
      treatment phase of 13-20 months, and a follow-up phase of 12-month after end of study&#xD;
      treatment. During the study treatment phase, participants will receive an MDR-TB regimen&#xD;
      consisting of 24 weeks of delamanid in combination with 13-20 months of a background regimen.&#xD;
&#xD;
      Participants will be instructed to take their assigned dose of delamanid with at least 3&#xD;
      additional probably effective background drugs according to national and international&#xD;
      guidelines. Delamanid dosage will be 100 mg twice daily (b.i.d.) for 24 weeks.&#xD;
&#xD;
      Safety evaluations will include monitoring of AEs, visual acuity testing, routine blood&#xD;
      examinations (such as hematology, clinical chemistry, HIV, TSH [for subjects receiving PTO]&#xD;
      measurements), urinalysis, and electrocardiograms (ECGs).&#xD;
&#xD;
      Participants will initiate treatment with the study regimen if they meet the study&#xD;
      eligibility criteria.The end of study will be considered as the last contact for the last&#xD;
      participant in the study.&#xD;
&#xD;
      A participant will be considered to have completed the study if he or she has completed the&#xD;
      13-20 months study treatment phase and the required post-treatment follow-up phase.&#xD;
      Participants who prematurely discontinue study treatment (unless they withdraw consent) will&#xD;
      be followed up for 12 months after end of delamanid treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants experiencing all-cause mortality</measure>
    <time_frame>from enrollment to the completion of the trial ,an average of 30-32months</time_frame>
    <description>the percentage of participants who died during the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants experiencing treatment-emergent AEs</measure>
    <time_frame>the whole treatment phase,an average of 18-20 months</time_frame>
    <description>the percentage of participants who experienced adverse effect during treatment phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants With Sputum Culture Conversion</measure>
    <time_frame>up to 24 weeks after enrollment</time_frame>
    <description>Sputum culture conversion is defined as 2 consecutive sputum cultures negative for multidrug-resistant tuberculosis (MDR-TB) taken at least 25 days apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Median Time to Sputum Culture Conversion</measure>
    <time_frame>upto 24 weeks after enrollment</time_frame>
    <description>Sputum culture conversion is defined as 2 consecutive sputum cultures negative for multidrug-resistant tuberculosis (MDR-TB) taken at least 25 days apart.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Multidrug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>delamanid containing regimen arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the only one arm to be studied with delamid-containing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delamanid</intervention_name>
    <description>the eligible patients will be give damanid-containing regimen</description>
    <arm_group_label>delamanid containing regimen arm</arm_group_label>
    <other_name>anti-TB new drug containing regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with microbiologically confirmed multidrug-resistant/rifampicin resistant&#xD;
             tuberculosis ;&#xD;
&#xD;
          2. Age 18 to 65 years old;&#xD;
&#xD;
          3. MDR-TB treatment has not been started, or treatment has been started but treatment&#xD;
             regimen need to be intensified;&#xD;
&#xD;
          4. According to the guidelines of WHO's consolidated guidelines for the treatment of&#xD;
             drug-resistant TB and the consensus of Chinese experts in the treatment of&#xD;
             multidrug-resistant and rifampicin resistant TB (2019 edition), effective treatment&#xD;
             regimens can only be formed by adding Delamanid based on the results of drug&#xD;
             susceptibility testing and the previous treatment history;&#xD;
&#xD;
          5. No history of respiratory failure, no history of cardiac dysfunction and clinically&#xD;
             significant arrhythmia, QTcF &lt; 450ms;&#xD;
&#xD;
          6. Patients should be able to take medicines and clinical monitoring according to the&#xD;
             requirements of the trial during the treatment and follow-up phases, and adverse&#xD;
             effects should be reported to the responsible doctor timely ;&#xD;
&#xD;
          7. Patients should sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of allergy to nitroimidazole and pyrrole drugs such as Delamanid,&#xD;
             metronidazole, tinidazole, or any excipient.&#xD;
&#xD;
          2. Serum transaminase increased ≥3 times the upper limit of normal value or total&#xD;
             bilirubin increased ≥2.5 times the upper limit of normal, serum albumin &lt;2.8 g / dL,&#xD;
             severe renal impairment.&#xD;
&#xD;
          3. Taking strong CYP3A4 inducer drugs (such as carbamazepine).&#xD;
&#xD;
          4. Is known to be pregnant (or planning to become pregnant) .&#xD;
&#xD;
          5. Participants took part in trials of other new unlisted drugs within the past three&#xD;
             months;&#xD;
&#xD;
          6. Congenital QT interval prolongation is known or has any disease that may prolong the&#xD;
             QT interval or QTc no less than 500 ms;&#xD;
&#xD;
          7. A history of symptomatic arrhythmia or suffering from clinically related bradycardia;&#xD;
&#xD;
          8. Any cardiac disease that can induce arrhythmias, such as severe hypertension, left&#xD;
             ventricular hypertrophy (including hypertrophic cardiomyopathy), or congestive heart&#xD;
             failure with reduced left ventricular ejection fraction;&#xD;
&#xD;
          9. Electrolyte disturbance, especially hypokalemia, hypocalcemia or hypomagnesemia;&#xD;
&#xD;
         10. Taking drugs known to prolong the QT interval such as the following drugs (but not&#xD;
             limited to) :&#xD;
&#xD;
             ① Anti-arrhythmic drugs, such as amiodarone, disopyramide, dofetilide, ibutilide,&#xD;
             procainamide, quinidine, hydroquinidine, sotalol, etc .;&#xD;
&#xD;
               -  Antipsychotic drugs, such as phenothiazine, sertindole, sultopride,&#xD;
                  chlorpromazine, haloperidol, mesoridazine, pimozide or thioridazine, and&#xD;
                  antidepressants; ③ Certain antibiotics, including:&#xD;
&#xD;
                    -  Macrolides, such as erythromycin, clarithromycin, etc ;&#xD;
&#xD;
                    -  Moxifloxacin, Sparfloxacin;&#xD;
&#xD;
                    -  Triazole antifungal drugs;&#xD;
&#xD;
                    -  Spray him with amidine;&#xD;
&#xD;
                    -  Saquinavir;&#xD;
&#xD;
                       ④ Some non-sedative antihistamines, such as terfenadine, astemizole,&#xD;
                       mizolastine, etc.&#xD;
&#xD;
         11. Other drugs with protential cardiac risk : cisapride, haloperidol, domperidone,&#xD;
             bepridil, diphemanil, probucol, dimepheptanol, methadone, vinblastine, arsenic&#xD;
             trioxide.&#xD;
&#xD;
        Deletion criteria:&#xD;
&#xD;
          1. Those who are found to have exclusion items after enrolled;&#xD;
&#xD;
          2. Serious adverse reactions caused by Delamanid, such as allergic reactions, mental&#xD;
             disorders, and liver injury (transaminases increase greater than 3 times the upper&#xD;
             limit of normal value or total bilirubin increase greater than 2.5 times the upper&#xD;
             limit of normal);&#xD;
&#xD;
          3. QTcF ≥500ms or clinically significant ventricular arrhythmia is confirmed;&#xD;
&#xD;
          4. The expert group made decision that it is not appropriate for the patient to continue&#xD;
             the treatment with Delamanid;&#xD;
&#xD;
          5. The patient cannot tolerate the background treatment regimen, or the modified&#xD;
             background treatment regimen cannot meet the 3 definitive sensitive drugs or 4&#xD;
             probably sensitive drugs;&#xD;
&#xD;
          6. The patient requests dropout.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jingtao jt Gao, PhD</last_name>
    <phone>+8610-89509131</phone>
    <email>jingtaogao@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chest Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Mengqiu Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changsha Central Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi Pei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Public Health Clinical Center of Chengdu</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Infectious Disease Medical Center</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaofeng Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou Pulmonary Hospital of Fujian</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaohong Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Chest Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinjie Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guiyang Public Health Clinical Center</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Cui Cai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heilongjiang Province center for tuberculosis Control and Prevention</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Long Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhou Red Cross Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingshan Cai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tuberculosis Hospital in Jilin Province</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peng Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Chest Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xusheng Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Kunming City</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Mingwu Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Longtan Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Liuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kangyan Lv</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei Chest Hospital</name>
      <address>
        <city>Shijiangzhuang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shujun Geng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth People Hospital of Suzhou</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peijun Tang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospital of Taiyuan</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanfang Miao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Institute For Tuberculosis Control</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan Du</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xi'an Chest Hospital</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Chest Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruixia Liang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chest Hospital</investigator_affiliation>
    <investigator_full_name>Liang Li</investigator_full_name>
    <investigator_title>Vice president</investigator_title>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>Delamanid</keyword>
  <keyword>effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

